Real-World Outcomes of Pembrolizumab in Advanced Melanoma by Age and Sex: A National Population-Based Study.

ABSTRACT:

Background

Immune checkpoint inhibitors are standard treatment for advanced melanoma. Pembrolizumab (programmed cell death-1 inhibitor) monotherapy is recommended as first-line treatment. However, real-world evidence on its efficacy and safety in Australia, a region with the highest melanoma incidence, remains limited.

Objective

This study aimed to assess real-world outcomes of pembrolizumab in patients with advanced melanoma in Australia.

Methods

A retrospective cohort study was conducted using national Pharmaceutical Benefits Scheme and National Death Index data via the Australian Bureau of Statistics DataLab. Patients who initiated pembrolizumab monotherapy for stage III/IV unresectable melanoma (1 January, 2017-30 June, 2022) were included. Kaplan-Meier analyses a

SUBMITTER: Yiu CH 

PROVIDER: S-EPMC12454464 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature